Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSLN.L Regulatory News (SLN)

  • There is currently no data for SLN

Form 8.5 (EPT/NON-RI)

13 Sep 2010 13:45

RNS Number : 5814S
Nomura Code Securities Limited
13 September 2010
 



FORM 8.5 (EPT/NON-RI)

 

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY AN

EXEMPT PRINCIPAL TRADER WITHOUT RECOGNISED INTERMEDIARY ("RI") STATUS (OR WHERE RI STATUS IS NOT APPLICABLE)

Rule 8.5 of the Takeover Code (the "Code")

 

1. KEY INFORMATION

 

(a) Name of exempt principal trader:

Nomura Code Securities Ltd

(b) Name of offeree in relation to whose relevant securities this form relates:

Silence Therapeutics Ltd

(c) Name of the party to the offer with which exempt principal trader is connected:

Silence Therapeutics Ltd

(d) Date dealing undertaken:

10 Sep 2010

(e) Has the EPT previously disclosed, or is it today disclosing, under the Code in respect of any other party to this offer?

 

NO

 

 

2. POSITIONS OF THE EXEMPT PRINCIPAL TRADER

 

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

 

Class of relevant security:

 

 

 

Interests

Short positions

Number

%

Number

%

(1) Relevant securities owned and/or controlled:

0

0.0

563,377

0.2

(2) Derivatives (other than options):

0

(3) Options and agreements to purchase/sell:

0

 

TOTAL:

0

0.0

563,377

0.2

 

All interests and all short positions should be disclosed.

 

Details of any open derivative or option positions, or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

 

(b) Rights to subscribe for new securities (including directors' and other executive options)

 

Class of relevant security in relation to which subscription right exists:

None

Details, including nature of the rights concerned and relevant percentages:

None

 

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

 

3. DEALINGS (IF ANY) BY THE EXEMPT PRINCIPAL TRADER

 

(a) Purchases and sales

 

Class of relevant security

Purchase/sale

 

Number of securities

Price per unit

Ord shares

Purchase

35,000

11.5 p

Total

Purchases:

35,000

Ord shares

Sale

428,449

11.67 p

Total

Sales:

428,449

 

(b) Derivatives transactions (other than options)

 

Class of relevant security

Product description

e.g. CFD

Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a long/short position

Number of reference securities

Price per unit

 

 

 

(c) Options transactions in respect of existing securities

 

(i) Writing, selling, purchasing or varying

 

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit

Type

e.g. American, European etc.

Expiry date

Option money paid/ received per unit

 

(ii) Exercising

 

Class of relevant security

Product description

e.g. call option

Number of securities

Exercise price per unit

 

 

 

(d) Other dealings (including subscribing for new securities)

 

Class of relevant security

Nature of dealing

e.g. subscription, conversion

Details

Price per unit (if applicable)

 

 

 

The currency of all prices and other monetary amounts should be stated.

 

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

 

4. OTHER INFORMATION

 

(a) Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

If there are no such agreements, arrangements or understandings, state "none"

 

None

 

 

(b) Agreements, arrangements or understandings relating to options or derivatives

 

Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

 

None

 

 

(c) Attachments

 

Is a Supplemental Form 8 (Open Positions) attached?

No

 

 

Date of disclosure:

13 Sep 2010

Contact name:

Niall Campbell

Telephone number:

020 7776 1226

 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk. The Panel's Market Surveillance Unit is available for consultation in relation to the Code's dealing disclosure requirements on +44 (0)20 7638 0129.

 

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
FEOUOSURRSAKAAR
Date   Source Headline
20th Sep 201712:02 pmRNSPrice Monitoring Extension
13th Sep 201712:07 pmRNSSecond Price Monitoring Extn
13th Sep 201712:02 pmRNSPrice Monitoring Extension
11th Sep 20171:30 pmRNSFurther Strengthens US Patent Estate
8th Sep 201712:07 pmRNSSecond Price Monitoring Extn
8th Sep 201712:02 pmRNSPrice Monitoring Extension
6th Sep 20177:00 amRNSInterim results for six months ended 30 June 2017
4th Sep 20177:00 amRNSNotice of Interim Results
23rd Aug 20177:00 amRNSSave the Date: Capital Markets Event 14 November
17th Aug 20174:05 pmRNSReplacement - Holding(s) in Company
17th Aug 20172:02 pmRNSDirector/PDMR Shareholding
15th Aug 20177:00 amRNSTwo further US patents to be granted
3rd Aug 20177:00 amRNSDirector/PDMR Shareholding
31st Jul 201711:43 amRNSDirector/PDMR Shareholding
31st Jul 20177:00 amRNSHolding(s) in Company
31st Jul 20177:00 amRNSUS patent to be granted
27th Jul 20172:43 pmRNSLicensee Quark Announces Positive AKI Results
24th Jul 20177:00 amRNSPresenting at Canaccord Genuity Growth Conference
24th Jul 20177:00 amRNSSilence Strengthens US Patent Estate
14th Jul 20177:00 amRNSCEO Ali Mortazavi appointed Chairman of Ultromics
10th Jul 20177:41 amRNSIP update
3rd Jul 20172:34 pmRNSIssue of claim in the UK High Courts
3rd Jul 20177:00 amRNSChange of Adviser
29th Jun 201711:47 amRNSHolding(s) in Company
6th Jun 20177:00 amRNSResult of AGM
1st Jun 20177:00 amRNSHiring of Chief Operating Officer
30th May 20177:00 amRNSSilence Continued Expansion of IP
16th May 20177:00 amRNSSignificant Expansion of Intellectual Property
4th May 201712:05 pmRNSNotice of AGM and Publication of Annual Report
3rd May 20177:00 amRNSSilence Therapeutics Presents New Data
12th Apr 20171:30 pmRNSAdditional Listing
3rd Apr 20177:00 amRNSGrant of Share Options to Directors
28th Mar 20177:00 amRNSPreliminary Results for the year to 31 Dec 2016
8th Mar 20177:00 amRNSNotice of Results
13th Jan 20172:03 pmRNSMinority Stake in Arrowhead Pharmaceuticals
9th Jan 20177:00 amRNSAcquisition of Minority Stake in Arrowhead
20th Dec 20167:00 amRNSSilence announces Quark arbitration resolution
15th Nov 20167:00 amRNSCRISPR/Cas9 Gene Editing Data
27th Sep 20167:00 amRNSHalf-year Report
22nd Sep 20167:00 amRNSNotice of Results
5th Sep 20167:00 amRNSAppointment of CSO and Non-Executive Director
18th Jul 20167:00 amRNSDirector/PDMR Shareholding
17th Jun 20163:48 pmRNSResult of AGM
1st Jun 20162:35 pmRNSHolding(s) in Company
24th May 20167:00 amRNSBoard Changes, Advisory Board and Notice of AGM
19th Apr 20167:00 amRNSDirector/PDMR Shareholding
18th Apr 20166:09 pmRNSDirector/PDMR Shareholding
18th Apr 20167:00 amRNSGrant of share options to Chief Executive
5th Apr 20167:00 amRNSAtu027 Update
5th Apr 20167:00 amRNSFinal Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.